Major findings supporting the involvement of CB2R in depressive disorders

Animal studies
Genetic studies Genetic manipulation Animal specie Experimental test Behavioral changes References
CB2xP Mouse, ICR TST ↓ immobility time [39]
NSFT ↓ latency time and ↑ food (g) consumption [39]
CMS ↑ resistance
(↑ sucrose 1% consumption and ↓ immobility time in TST)
[39]
CB2–/– Mouse, ICR TST ↑ immobility time [44]
DAT-Cnr2–/– Mouse, C57BL/6J TST, FST ↑ immobility time [69]
Pharmacological studies Drug Animal specie Experimental test Dosis Behavioral changes References
AM630 (CB2R antagonist) Mouse, ICR CMS 1 mg/kg per 12 h (4 weeks) Antidepressive actions (↑ immobility time in TST and ↑ sucrose 1% consumption) [39]
Mouse, BALB/c
C57BL/6J
CMS 3 mg/kg per 24 h (4 weeks) No effect [45]
Human studies
Variable Population Results References
Q63R polymorphism Japanese ↑ incidence [45]
CB2R expression Caucasian ↓ in DLPFC and amygdala [56]

TST: tail suspension test; NSFT: novelty suppressed feeding test; FST: forced swimming test; CMS: chronic mild stress